Risk of thromboembolism in non-small-cell lung cancers patients with different oncogenic drivers, including ROS1, ALK, and EGFR mutations
Journal
ESMO open
Journal Volume
7
Journal Issue
6
Date Issued
2022-12-06
Author(s)
Abstract
Anaplastic lymphoma kinase-positive (ALK+) and ROS proto-oncogene 1 (ROS1)-positive (ROS1+) lung cancers have been reported to be associated with an elevated risk of thromboembolic events. This study aimed to assess the long-term risk of developing thromboembolism (TE) in ROS1+ lung cancer and to compare it with other oncogenic drivers in the Asian population.
Subjects
ALK; EGFR; ROS1 rearrangement; non-small-cell lung cancer; thromboembolism
SDGs
Type
journal article